RCT: Apixaban is not superior to the standard of care (vitamin K antagonist or antiplatelet therapy if anticoagulation is indicated or not, respectively) after transcatheter aortic valve implantation.

Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial – European Heart Journal (link to abstract – $ for full-text)

Editorial: Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS – European Heart Journal

Related:

Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial – Circulation

Comparing Single- and Dual-Antiplatelet Therapies After Transcatheter Aortic Valve Implantation – The Annals of Thoracic Surgery

Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient‐Level Meta‐Analysis – Journal of the American Heart Association

Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation – New England Journal of Medicine

Anti-Thrombotic Strategy to Lower All cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis – ATLANTIS – American College of Cardiology